Delving into the Latest Updates on SER-140 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

IL1R1

Mechanism

IL1R1 antagonists(Interleukin-1 receptor antagonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2Diabetic Nephropathies

Originator Organization

Serodus ASA

Active Organization-

Inactive Organization

Serodus ASA

Drug Highest PhaseDiscontinuedPreclinical

First Approval Date-

Regulation-

The cytokine interleukin-1β(IL-1β) is known to stimulate proinflammatory immune responses and impairβ-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1βreceptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1βactivated pathways.

100 Deals associated with SER-140

Login to view more data